Cost-effectivness of CAR T-cell therapy for pALL. A societal view.
In this article we conduct a cost-utility analyses of the CAR T-cell therapy tisagenlecleucel from a health care perspective and societal perspective.
Second‐line treatment for acute graft‐versus‐host disease with mesenchymal stromal cells: A decision model.
In this article we describe the development and simulation of a decision model for the second-line treatment of acute GvHD.